Application of 5-oxyproline in preparing medicine for preventing or treating cardiomyopathy

By combining 5-oxyproline with other components, a cardiomyopathy drug is prepared for the treatment of chemotherapy-induced cardiomyopathy in patients with tumors, the cardiomyotoxicity and irreversible structural changes caused by chemotherapy drugs are solved, and the recovery of cardiac function and heart weight is achieved. The improvement of cardiomyocytes significantly reduces the mortality rate of cancer patients with cardiovascular disease.

CN118831080BActive Publication Date: 2024-11-22RENJI HOSPITAL AFFILIATED TO SHANGHAI JIAO TONG UNIV SCHOOL OF MEDICINE
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202411329277.9
Authority / Receiving Office
CN · China
Patent Type
Patents(China)
Current Assignee / Owner
Filing Date
2024-09-24
Publication Date
2024-11-22
Estimated Expiration
2044-09-24

AI Technical Summary

Technical Problem

The myocardial toxicity and irreversible structural changes caused by anthracyclines in chemotherapy in tumor patients lead to heart failure, and the existing preventive measures are lacking in targeted and effective.

Method used

Use 5-oxyproline to combine with other active ingredients or excipients to prepare cardiomyopathy drugs for preventing or treating chemotherapy-induced cardiomyopathy drugs, targeting irreversible structural changes in the myocardial function, decreased heart function, and cardiac muscle cells caused by chemotherapy drugs. Symptoms such as atrophy, fibrosis and oxidative stress have the effect of restoring and improving.

Benefits of technology

5-Oxyproline significantly restores decreased cardiac function and cardiac weight, improves cardiomyocyte atrophy and fibrosis, reduces oxidative stress and apoptosis in myocardial tissue, and provides an effective treatment for chemotherapy-induced cardiomyopathy and reduces tumors. The mortality rate of patients dying from cardiovascular disease.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN118831080B_ABST
    Figure CN118831080B_ABST
Patent Text Reader

Abstract

The present invention discloses a new use of 5-oxyproline in preparing a drug for preventing or treating cardiomyopathy, especially a new use in preventing or treating cardiomyopathy induced by chemotherapy in tumor patients. Through further research on chemotherapy-induced cardiomyopathy in tumor patients, the present invention finds that 5-oxyproline can partially restore decreased cardiac function, improve myocardial cell atrophy and myocardial tissue fibrosis, and reduce myocardial tissue oxidative stress and myocardial cell apoptosis. It can be used to prevent or treat chemotherapy-induced cardiomyopathy in tumor patients, solves the problem that there is currently no small molecule metabolite treatment for chemotherapy-induced cardiomyopathy in tumor patients, is expected to significantly reduce the mortality of tumor patients from cardiovascular diseases, and has important clinical prevention and treatment significance.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The invention discloses a new application of 5-oxyproline, in particular, an application of 5-oxyproline in preparing a drug for preventing or treating chemotherapy-induced cardiomyopathy in tumor patients. Background Art

[0002] Heart failure is the terminal stage of various cardiovascular diseases, with high mortality and disability rates. It is the last bastion to be conquered in the cardiovascular field. Among them, heart failure in tumor heart disease has become an emerging frontier. While various types of chemotherapy drugs bring survival benefits, there are also various adverse drug reactions, especially heart damage caused by chemotherapy. One-third of cancer patients die from cardiovascular disease rather than the tumor itself, which is currently the leading cause of non-cancer related deaths in cancer patients.

[0003] Anthracyclines, the most classic chemotherapy drugs for tumor treatment, are widely used in clinical treatment due to their powerful therapeutic effects. However, their clinical application is largely affected by cumulative and dose-dependent cardiotoxicity, which may eventually lead to irreversible structural changes in the myocardium and progressive heart failure. Currently, dexrazoxane is the only drug approved by the FDA for the prevention of anthracycline-induced cardiotoxicity, but due to its severe side effects of bone marrow suppression, it is contraindicated in children with hematological tumors. In addition, there are studies trying to prevent breast cancer treatment-related cardiac insufficiency (anthracyclines, trastuzumab) with anti-heart failure drugs such as angiotensin-converting enzyme inhibitors, angiotensin receptor blockers, and beta-blockers, but these drugs are not targeted medications, and there is no consensus on their efficacy, timing of use, and applicable population.

[0004] Therefore, specifically and effectively preventing or reversing the aggravation of chemotherapy-induced myocardial damage in cancer patients can effectively reduce non-cancer cardiovascular mortality and improve the overall survival prognosis of cancer chemotherapy patients. Summary of the invention

[0005] The object of the present invention is to provide the use of 5-oxoproline (5-OXO) in the preparation of a drug for preventing or treating chemotherapy-induced cardiomyopathy in tumor patients.

[0006] To achieve the purpose of the present invention, the technical solution adopted by the present invention is: use of 5-oxyproline in preparing a drug for preventing or treating cardiomyopathy.

[0007] The inventors of the present application have discovered a new application of 5-oxyproline in the prevention or treatment of cardiomyopathy. 5-oxyproline can be combined with other active ingredients or excipients to prepare a drug for the prevention or treatment of cardiomyopathy, providing a new treatment option for the treatment of cardiomyopathy.

[0008] As a preferred embodiment of the use of 5-oxyproline in the present invention in the preparation of a drug for preventing or treating cardiomyopathy, the cardiomyopathy is cardiomyopathy induced by chemotherapy in tumor patients. The new application of 5-oxyproline in the prevention or treatment of cardiomyopathy found in the present application, the cardiomyopathy particularly refers to cardiomyopathy induced by chemotherapy in tumor patients, especially due to the accumulation and dose-dependence of chemotherapeutic drugs during chemotherapy, which leads to irreversible structural changes in the myocardium, progressive heart failure, and other induced cardiomyopathy.

[0009] As a preferred embodiment of the use of 5-oxoproline in the present invention in the preparation of a drug for preventing or treating cardiomyopathy, the drug used for chemotherapy is an anthracycline drug. More preferably, the anthracycline drug is doxorubicin. The chemotherapy drug is preferably, but not limited to, anthracycline drugs, such as doxorubicin, etc. The 5-oxoproline has a good effect on the prevention or treatment of cardiomyopathy, especially on cardiomyopathy induced by anthracycline, a classic drug currently used in the treatment of tumor patients.

[0010] In addition, the present invention also provides the use of 5-oxyproline in the preparation of any one of the drugs for restoring decreased cardiac function, restoring decreased heart weight, improving myocardial cell atrophy, improving myocardial tissue fibrosis, reducing myocardial tissue oxidative stress, and reducing myocardial cell apoptosis. The inventors of the present application have found in their research that 5-oxyproline has a certain restorative effect on decreased cardiac function and heart weight, can improve myocardial cell atrophy and myocardial tissue fibrosis, and can also reduce myocardial tissue oxidative stress and myocardial cell apoptosis, and can be used to prepare drugs with any one of the functions of restoring cardiac function and heart weight, improving myocardial cell atrophy, improving myocardial tissue fibrosis, reducing myocardial tissue oxidative stress, and reducing myocardial cell apoptosis.

[0011] Preferably, the aforementioned decrease in cardiac function, decrease in heart weight, myocardial cell atrophy, myocardial tissue fibrosis, myocardial tissue oxidative stress, and myocardial cell apoptosis are induced by chemotherapy in tumor patients. In the new application of 5-oxoproline, especially for the decrease in cardiac function, decrease in heart weight, myocardial cell atrophy, myocardial tissue fibrosis, myocardial tissue oxidative stress, and myocardial cell apoptosis caused by chemotherapy in tumor patients, 5-oxoproline has a good recovery and improvement effect on these symptoms caused by chemotherapy drugs.

[0012] Preferably, the drug used in the chemotherapy is an anthracycline drug. More preferably, the anthracycline drug includes common drugs currently used in clinical chemotherapy, such as but not limited to doxorubicin. The above symptoms are generally caused by the accumulation and dosage of chemotherapy drugs, especially the irreversible structural changes and damages caused by the accumulation and dosage of anthracycline chemotherapy drugs to cardiac function, such as but not limited to doxorubicin, etc. The 5-oxyproline has a good preventive and therapeutic effect on the above irreversible structural changes and damages of the myocardium induced by these chemotherapy drugs.

[0013] Finally, the present invention also provides a drug for preventing or treating chemotherapy-induced cardiomyopathy in tumor patients, the drug comprising 5-oxoproline and a pharmaceutically acceptable carrier. The 5-oxoproline described in the present invention can be prepared together with a pharmaceutically acceptable carrier to form a drug for preventing or treating chemotherapy-induced cardiomyopathy in tumor patients.

[0014] Preferably, the drug can be prepared into various dosage forms in the art, for example including but not limited to injections.

[0015] Through further research on chemotherapy-induced cardiomyopathy in cancer patients, the present invention discovered that 5-oxoproline can partially restore decreased cardiac function and heart weight, improve cardiomyocyte atrophy and myocardial tissue fibrosis, reduce myocardial tissue oxidative stress and cardiomyocyte apoptosis, and can be used to prevent or treat chemotherapy-induced cardiomyopathy in cancer patients. This solves the problem that there is currently no small molecule metabolite treatment for chemotherapy-induced cardiomyopathy in cancer patients, and is expected to significantly reduce the mortality rate of cancer patients from cardiovascular disease, which has important clinical prevention and treatment significance. BRIEF DESCRIPTION OF THE DRAWINGS

[0016] Figure 1 The figure shows the changes of 5-oxyproline in the serum and myocardial tissue of mice and its correlation with early cardiac function decline.

[0017] Figure 2 Cell curves of the control group, DOX group, and DOX+5-OXO group.

[0018] Figure 3 The figure shows the body weight changes and heart weight / body weight ratio of mice in the control group, 5-OXO group, DOX group, and DOX+5-OXO group after drug administration.

[0019] Figure 4 Ultrasound detection images of the left ventricle in the control group, 5-OXO group, DOX group, and DOX+5-OXO group.

[0020] Figure 5This is a comparison chart of the changes in left ventricular end-systolic volume (LVEDV), ejection fraction (EF%), short-axis contraction fraction (FS%) and stroke volume (CO) in the control group, 5-OXO group, DOX group and DOX+5-OXO group.

[0021] Figure 6 Masson staining images and quantitative statistical graphs of myocardial collagen area in the control group, 5-OXO group, DOX group, and DOX+5-OXO group.

[0022] Figure 7 These are the gross images and HE staining images of the hearts in the control group, 5-OXO group, DOX group, and DOX+5-OXO group.

[0023] Figure 8 These are the WGA staining images and statistical graphs of the cross-sectional area of ​​myocardial cells in the control group, 5-OXO group, DOX group, and DOX+5-OXO group.

[0024] Fig. 9 These are the results of 4-HNE immunohistochemical staining of myocardial tissue in the control group, 5-OXO group, DOX group, and DOX+5-OXO group.

[0025] Fig.10 This is the cardiomyocyte apoptosis status and statistical analysis of apoptotic cells in the control group, 5-OXO group, DOX group, and DOX+5-OXO group. DETAILED DESCRIPTION

[0026] In order to better illustrate the purpose, technical solutions and advantages of the present invention, the present invention will be further described below in conjunction with the accompanying drawings and specific embodiments.

[0027] Example 1

[0028] Changes of 5-Oxyproline in the blood in the early stage of anthracycline-induced cardiomyopathy

[0029] 1. Experimental animals and groups

[0030] A total of 16 C57 mice aged 6-8 weeks were selected and randomly divided into an experimental group and a control group, with 8 mice in each group.

[0031] The mice in the experimental group were given a tumor cardiomyopathy model (doxorubicin, 5 mg / kg, once), and cardiac function was evaluated by cardiac ultrasound one week later.

[0032] 2. Extraction of metabolites from blood

[0033] (1) The experimental group mice and the control group mice were anesthetized after tumor heart disease modeling, and the hearts were removed. The hearts were washed with pre-cooled 4°C saline, the residual blood was drained, and part of the apex of the heart was quickly frozen with liquid nitrogen for myocardial tissue metabolome analysis;

[0034] (2) After slowly thawing the myocardial tissue frozen in liquid nitrogen at 4°C, take an appropriate amount of sample and add it to pre-cooled methanol / acetonitrile / water solution (2:2:1, v / v), vortex mix, low-temperature ultrasonicate for 30 min, let stand at -20°C for 10 min, centrifuge at 14000g for 20 min at 4°C, take the supernatant and vacuum dry, add 100 μL acetonitrile aqueous solution (acetonitrile: water = 1:1, v / v) for re-dissolution during mass spectrometry analysis, vortex, centrifuge at 14000g for 15 min at 4°C, take the supernatant to obtain the metabolic extract.

[0035] 3. Detection of 5-Oxyproline Content

[0036] The metabolic extract is used as a sample to detect the 5-oxyproline content therein, and the detection method is as follows:

[0037] (1) Sample pretreatment

[0038] Synthesis of 5-oxoproline internal standard: Prepare 1 mg / mL glutamic acid-d5 solution with 0.1N hydrochloric acid, heat at 80°C for 15 hours to synthesize 5-oxoproline-d5 internal standard solution, and adjust the pH back to neutral with ammonia water to prepare 5-oxoproline internal standard;

[0039] Preparation of internal standard working solution: dilute the 5-oxoproline internal standard 200 times with 75% acetonitrile aqueous solution containing 0.2% formic acid to prepare the 5-oxoproline internal standard working solution;

[0040] Sample processing: Take 50 μL of the standard curve, quality control product and the sample to be tested and add them to a 1.5 mL centrifuge tube, add 400 μL of the internal standard working solution, vortex for 60 seconds, centrifuge at 13000 rpm and 4 degrees for 10 minutes, aspirate 200 μL of the supernatant and transfer it to a 2.2 mL 96-well plate, and wait for loading on the machine.

[0041] (2) Liquid phase method

[0042] The metabolites in the sample were separated by a chromatographic column Phenomenex Kinetex F5 (2.6um, 2.1×100mm). The specific chromatographic conditions were as follows:

[0043] Mobile phase A was 0.1% formic acid in water;

[0044] Mobile phase B was 0.1% formic acid acetonitrile;

[0045] Flow rate: 0.25 ml / min;

[0046] The column temperature was 25°C;

[0047] The gradient elution conditions are shown in Table 1 below.

[0048] Table 1 Gradient elution conditions

[0049]

[0050] (3) Mass spectrometry method

[0051] AB SCIEX Triple Quad™ 4500MD liquid chromatography tandem mass spectrometry detection system, using ESI+, multiple reaction monitoring (MRM) mode for mass spectrometry scanning; Curtain Gas (CUR) is 35 psi; Collision Gas (CAD) is 9 psi; Voltage is +5500V; Desolvation gas temperature is 500℃; Heating gas (GS1) is 50psi; Auxiliary gas (GS2) is 50psi. The mass spectrometry channel parameters are shown in Table 2 below.

[0052] Table 2 Mass spectrometry channel parameters

[0053]

[0054] (4) Calibration products and quality control products

[0055] The 5-oxoproline standard was prepared with water to form a 50 mM primary stock solution, which was diluted with water to form a 4 mM secondary stock solution, which was then diluted with water and mixed to obtain standard curves and quality control products of different concentrations, as shown in Table 3 below.

[0056] Table 3 Standard and quality control products of different concentrations

[0057]

[0058] The test results are as attached Figure 1 As shown. Figure 1 It can be seen that the content of 5-oxoproline in the blood of mice with doxorubicin-induced cardiomyopathy decreased significantly and was negatively correlated with the global longitudinal strain (GLS), an indicator of early cardiac function decline.

[0059] The inventors of the present application first discovered that the content of 5-oxoproline is significantly decreased in chemotherapy-induced cardiomyopathy, and based on this discovery, further studied chemotherapy-induced cardiomyopathy in cancer patients and found that 5-oxoproline can partially restore decreased cardiac function and heart weight, improve myocardial cell atrophy and myocardial tissue fibrosis, and reduce myocardial tissue oxidative stress and myocardial cell apoptosis.

[0060] Example 2

[0061] Effect of Oxyproline on Doxorubicin-induced Toxicity in Primary Rat Cardiomyocytes

[0062] 1. Extraction and culture of primary neonatal rat cardiomyocytes (NRCMs)

[0063] Twenty 1-3 day old Sprague-Dawley rats (purchased from the Animal Experiment Center of Renji Hospital) were used. After being first immersed in 70% alcohol for a few seconds for disinfection, the rats were cut open vertically from the armpits with instruments, and the hearts were clamped with curved forceps. After the hearts were cleaned in PBS, they were placed in a conical flask and injected with about 8 ml of digestion solution (25 ml 2 mg / ml collagenase II, 23 ml 0.25% pancreatin without EDTA, and 2 ml PBS) each time. The conical flask was placed on a constant temperature magnetic stirrer, the temperature was set to 37 ° C, the speed was 200 rpm, and the first stirring digestion was carried out for 20 minutes. The supernatant was collected, the residue was discarded, and the digestion solution was added again for the second 15 minutes of digestion. The supernatant was collected again, the residue was discarded, and mechanical digestion was carried out on the stirrer for about 10 minutes each time. During the third digestion, the washed heart was placed in a 5% serum DMEM medium and vigorously pipetted to neutralize the digestion solution. This process was repeated until the heart was completely digested or only fibers remained.

[0064] Then, the treated heart supernatant was centrifuged at 1200 rpm, and the supernatant was discarded. 2 ml of red blood cell lysis solution was added to each tube of cells to disperse them, and after standing in the lysis solution for 2 minutes, culture medium was added to polymerize the cells.

[0065] Finally, centrifuge again and adjust the centrifugation conditions to 1000 rpm and centrifugation time for 5 minutes. After discarding the cell supernatant after centrifugation, add the cells to complete medium, pipette and resuspend, then place them in a 100mm culture dish in an incubator and allow differential attachment for 90 minutes. Next, pipette the culture medium in the culture dish into a new 50ml centrifuge tube for counting, plate as needed, and then culture the cells with complete medium and add 100μM bromodeoxyuridine (Brdu) to inhibit fibroblast growth. After 48 hours, replace the serum-free medium to treat the cells.

[0066] 2. Construction of doxorubicin-induced primary cardiomyocyte injury model

[0067] Dissolve 1 mg of doxorubicin in 3.68 mL of PBS to prepare a 0.5 mM doxorubicin stock solution. Dissolve 1.29 mg of 5-oxyproline in 10 mL of PBS to prepare a 1 mM 5-oxyproline stock solution. Primary cardiomyocyte seeding density 2 × 10 5 / mL density was inoculated in a 96-well cell culture plate. The culture medium for the first two days of culture was a high-glucose DMEM seed plate medium containing BrdU and 10% serum, and on the third day, it was replaced with a high-glucose DMEM medium. After the cell state stabilized, the cell culture medium was evenly divided into three groups: control group, DOX group, and DOX+5-OXO group. The groups were as follows:

[0068] Control group: add the same volume of PBS;

[0069] DOX group: add the corresponding volume of doxorubicin stock solution to the working concentration (1uM);

[0070] DOX+5-OXO group: Add the same amount of doxorubicin stock solution and 5-oxoproline stock solution with concentration gradient as that of the DOX group to reach the working concentration (1uM, 2uM, 5uM).

[0071] Each group was cultured in constant temperature medium for 24 h before CCK8 experiment.

[0072] 3. CCK-8 cell activity detection

[0073] After the above groups of neonatal rat cardiomyocytes (NRCMs) were incubated in a constant temperature incubator for 24 hours, the cell surface was first washed with PBS, and then the cells were incubated with high-glucose DMEM medium containing 10% CCK-8 reagent in a light-proof environment at 37°C for 2 hours. After incubation, the absorbance was measured at 450nm with an ELISA reader, and the cell activity curve was drawn. The results are shown in the attached figure. Figure 2 shown.

[0074] By the attached Figure 2 It can be seen that 5-OXO can effectively reduce the cardiomyocyte toxicity caused by DOX, and the improvement effect of 5-OXO supplementation concentration of 5uM is the most obvious.

[0075] Example 3

[0076] Experiment on the intervention of 5-oxyproline on cardiac function of mice with adriamycin-induced myocardial injury The instruments and reagents used in this example are shown in Tables 4 and 5 below, respectively.

[0077] Table 4 Main instruments and equipment of this example

[0078]

[0079] Table 5 Main reagents in this example

[0080]

[0081] 1. Experimental animals and groups

[0082] 32 SPF male C57 mice, 6-8 weeks old, weighing about 25 g, were provided by the Experimental Animal Center of Renji Hospital Affiliated to Shanghai Jiao Tong University. The experiment was carried out after 3 days of adaptive feeding in the Experimental Animal Center. During the feeding period, the mouse breeding room was kept clean, with constant temperature and humidity (temperature 23±1℃, humidity 40±5%), and a 12-hour light and dark cycle. All experiments followed the guidelines of experimental animal ethics and were reviewed and approved by the Animal Ethics Committee of Renji Hospital Affiliated to Shanghai Jiao Tong University.

[0083] The mice were randomly divided into control group (Ctrl), 5-oxoproline group (5-OXO), doxorubicin group (DOX), and doxorubicin + 5-oxoproline group (DOX + 5-OXO). The drug administration conditions of each group were as follows:

[0084] 5-OXO group: 5-OXO was intraperitoneally injected (0.05 mg / kg) once a day;

[0085] Doxorubicin group (DOX): Doxorubicin (5 mg / kg) was intraperitoneally injected once a week;

[0086] Doxorubicin + 5-oxoproline group (DOX + 5-OXO): administration of doxorubicin + 5-oxoproline, the dosage was the same as that of the 5-oxoproline group (5-OXO) and doxorubicin group (DOX);

[0087] Control group: given the same amount of saline solution as the doxorubicin + 5-oxoproline group (DOX + 5-oxo);

[0088] Each group was administered the drug for 4 consecutive weeks, and the mice were weighed weekly during the administration.

[0089] The mice were modeled and administered medication for 4 weeks and then observed for 1 week. A cardiac color Doppler ultrasound examination (Vevo ultra-high resolution multimodal small animal ultrasound photoacoustic imaging system) was performed and samples were collected. After sampling, the heart was dried and weighed.

[0090] The results of body weight and heart weight changes of mice in each group after administration are shown in the attached figure. Figure 3 As shown. Figure 3 It can be seen that as the administration time increases, the body weight and heart weight of mice in the doxorubicin group (DOX) decrease significantly, the body weight of mice in the 5-oxoproline group (5-oxo) decreases slightly compared with the control group, and the body weight and heart weight of mice in the doxorubicin + 5-oxoproline group (DOX+5-OXO) are partially restored compared with the doxorubicin group (DOX). This shows that 5-oxoproline (5-OXO) can restore the decreased body weight and heart weight of mice.

[0091] Then, pathological tissue tests were performed on the myocardial tissues of each group: HE and Masson staining were used to observe the pathological changes of myocardial tissues; WGA staining was used to observe the changes in the size of myocardial cells; 4-HNE staining was used to detect the degree of oxidative stress in myocardial cells; and TUNEL staining was used to detect the apoptosis index of myocardial cells.

[0092] 2. Mouse heart ultrasound detection

[0093] Vevo ultra-high resolution small animal ultrasound imaging system and high-frequency probe were used for cardiac ultrasound examination of mice, and the cardiac function of the control group, 5-OXO group, DOX group, and DOX+5-OXO group was detected 4 weeks after administration.

[0094] Before the experiment, the hair on the mouse chest was removed with depilatory cream, and the mouse was anesthetized with half dose of isoflurane inhalation anesthesia and maintained spontaneous breathing. Then, short-axis section images were obtained at the parasternal left ventricular papillary muscle position to evaluate the left ventricular condition. At the same time, M-mode echocardiography records of 15 cardiac cycles were recorded using guided two-dimensional mode, and the left ventricular end-diastolic volume (LVEDV) was measured. The test results are shown in the attached Figure 4 and 5 shown.

[0095] By the attached Figure 4 and 5 The results of M-mode ultrasound examination of the left ventricle and the functional level of the heart showed that 5-oxoproline intervention significantly restored the reduced left ventricular end-diastolic volume (LVEDV) and alleviated the degree of cardiac atrophy induced by doxorubicin; at the same time, it significantly increased the ejection fraction (EF%), short-axis contraction rate (FS%) and stroke volume (CO), and improved myocardial contractile function and compliance.

[0096] 2. Pathological tissue detection

[0097] 2.1 Preparation of mouse heart paraffin sections

[0098] The mouse hearts of the above groups after modeling were sampled, washed with PBS, and the excess tissue was cut off. Then the hearts were fixed in 4% paraformaldehyde for 24 hours and stored in a 4°C refrigerator. After fixation, the hearts were placed in a tissue embedding box for dehydration. After the embedding machine paraffin melted, the embedding box was placed in the preheated embedding machine tissue slot, and the wax was dipped twice in slot No. 1 and three times in slot No. 2. After the tissue dehydration was completed, the sample was placed in the wax-soaked embedding box, and a small amount of wax liquid was added, and the embedding box was closed and cooled. At this time, the embedding was completed.

[0099] Take the embedded wax block and fix it on the pre-cooled paraffin slicer, adjust the slice thickness to 10μm, and the slice thickness to 3μm. After cutting the wax slice, spread it in a 40℃ preheated water tank with a brush, then pick it up with a slide and place it on a baking machine for 30 minutes.

[0100] 2.2 Masson staining

[0101] After dewaxing, the slices were washed in ddH2O for 3×5 min on a shaker at 40 rpm. Then, a circle was drawn around the heart with a histology pen and allowed to dry. The slices were then stained in the following steps:

[0102] (1) The sections were placed in mordant solution for mordant, incubated in a 60°C oven for 1 h, and then washed with ddH2O for 3 × 5 min.

[0103] (2) Dye with lapis lazuli blue staining solution, incubate at room temperature for 3 min, and then wash with ddH2O for 2 × 15 s;

[0104] (3) Mayer's hematoxylin staining solution was dripped for 3 min, and then washed with ddH2O for 2 × 15 s;

[0105] (4) Differentiation in acidic differentiation solution for 5 seconds, followed by rinsing with ddH2O for 10 minutes;

[0106] (5) Dye with Ponceau fuchsin solution for 10 min, and wash with ddH2O for 2 × 15 s;

[0107] (6) Add phosphomolybdic acid dye solution for 10 minutes;

[0108] (7) After removing the phosphomolybdic acid, add aniline blue dye solution directly for 5 minutes;

[0109] (8) After washing away the aniline blue with acetic acid solution, add weak acid solution and incubate for 2 min;

[0110] (9) Dehydrate with 95% ethanol for 30 s, dehydrate with anhydrous ethanol for 2 × 10 s, dehydrate with xylene for 2 × 5 s, and seal with neutral gum.

[0111] The staining results are shown in the attached Figure 6 As shown. Figure 6 It can be seen that Masson staining showed obvious myocardial fibrosis in the DOX group, while 5-oxoproline could significantly reduce myocardial fibrosis.

[0112] 2.3 HE staining

[0113] After dewaxing, the slices were soaked in distilled water for 2 minutes. Then, the slice tissue pen was used to circle the tissue slice area. After the tissue pen blot was completely dry, hematoxylin staining solution was added for 15 minutes, and the floating color was washed away by distilled water. Differentiation solution was added to differentiate the slices for 30 seconds, and tap water was used to wash for 2×5 minutes. Finally, eosin staining solution was added for 1 minute. After staining, the residual stain was washed away with distilled water and then dehydrated quickly. The dehydration steps are as follows:

[0114] (1) Soak in 75% ethanol, 85% ethanol, 95% ethanol, and 100% ethanol for 3 seconds;

[0115] (2) Soak in 100% ethanol for 1 min, then add xylene to wash away impurities for 2×1 min, and seal the slides with neutral gum.

[0116] After sealing, the slides were observed and analyzed under a microscope. The results are shown in the attached Figure 7 shown.

[0117] 2.4 WGA staining

[0118] Remove the paraffin sections, dewax and hydrate. Place the sections in a microplate containing PBS (phosphate buffered saline), one well for each sample. Add 0.1% Triton X-100 (in PBS), incubate for 10 minutes, and wash three times with PBS. Add WGA solution for staining. The concentration and time of WGA can be optimized according to experimental needs. Usually the WGA concentration is 5-20 µg / mL and the staining time is 30-60 minutes. Wash three times with PBS, 5 minutes each time. Add DAPI (4',6-diamidino-2-phenylindole) staining solution, incubate for 10 minutes, and wash three times with PBS. Invert the slide, add an appropriate amount of anti-browning glue to cover, and observe the fluorescence. The results are shown in the attached figure. Figure 8 shown.

[0119] By the attached Figure 7 and attached Figure 8 It can be seen that the cardiomyocytes in the control group were normal in morphology; obvious cardiomyocyte atrophy was found in the DOX group, and 5-oxyproline could significantly intervene in the cardiomyocyte atrophy caused by DOX.

[0120] 2.5 4-HNE immunohistochemical staining

[0121] The paraffin sections of the heart were dewaxed, antigen repaired, permeabilized, blocked, and probed with primary antibody (4°C, overnight), followed by incubation with secondary antibody for another 1 h at room temperature. SP (streptavidin-peroxidase) was added and then developed with DAB for 5-10 min, the reaction was terminated, counterstained with hematoxylin for 2 min, differentiated with hydrochloric acid alcohol, dehydrated, transparentized, and mounted as usual. The results are shown in the attached Fig. 9 shown.

[0122] By the attached Fig. 9 It can be seen that the degree of oxidative stress in mouse cardiomyocytes was detected by 4-HNE immunohistochemical staining, and it was found that the degree of oxidative stress in the myocardial tissue of mice in the DOX group was significantly increased compared with that in the control group, while the level of oxidative stress in the myocardial tissue of mice was significantly decreased after the corresponding 5-oxyproline intervention.

[0123] 2.9 Tunel staining

[0124] Dewax the paraffin sections of the heart, perform antigen repair, and then permeabilize and block. Prepare an appropriate amount of TUNEL detection solution (TdT enzyme: fluorescent labeling solution = 1:9) and mix thoroughly. Add 50μl of TUNEL detection solution to the sample and incubate at 37℃ in the dark for 60 minutes. Wash three times with PBS, seal the sections with anti-fluorescence quenching sealing solution, and observe under a fluorescence microscope. The results are shown in the attached figure. Fig.10 shown.

[0125] By the attached Fig.10 It can be seen that by detecting the apoptosis of mouse cardiomyocytes through TUNEL, it was found that the number of apoptotic cells in the myocardium of mice in the DOX group was significantly increased compared with the control group, while the number of apoptotic cells in the myocardium of mice intervened by 5-oxyproline was significantly reduced compared with the DOX group.

[0126] From the above experimental contents, it can be known that 5-oxoproline can partially restore the decreased cardiac function and heart weight, improve myocardial cell atrophy and myocardial tissue fibrosis, reduce myocardial tissue oxidative stress and myocardial cell apoptosis, and can be used to prevent or treat chemotherapy-induced cardiomyopathy in cancer patients. The inventors of this application first discovered that the level of 5-oxoproline is significantly decreased in chemotherapy-induced cardiomyopathy, and through further research on the mechanism of chemotherapy-induced cardiomyopathy, they finally found that 5-oxoproline has a good effect on preventing or treating chemotherapy-induced cardiomyopathy in cancer patients, and provided a small molecule metabolite for chemotherapy-induced cardiomyopathy in cancer patients as a therapeutic drug, which has important clinical significance.

[0127] Finally, it should be noted that the above embodiments are only used to illustrate the technical solution of the present invention rather than to limit the scope of protection of the present invention. Although the present invention has been described in detail with reference to the preferred embodiments, those skilled in the art should understand that the technical solution of the present invention can be modified or replaced by equivalents without departing from the essence and scope of the technical solution of the present invention.

Claims

The invention discloses an application of 1.5-oxyproline in the preparation of a drug for preventing or treating cardiomyopathy, wherein the cardiomyopathy is cardiomyopathy induced by chemotherapy in tumor patients, and the drug used in the chemotherapy is an anthracycline drug.

2. The use of 5-oxyproline in the preparation of a drug for preventing or treating cardiomyopathy according to claim 1, characterized in that: The anthracycline drug is doxorubicin. The use of 3.5-oxyproline in the preparation of a drug for restoring decreased cardiac function, restoring decreased heart weight, improving myocardial cell atrophy, improving myocardial tissue fibrosis, reducing myocardial tissue oxidative stress, and reducing myocardial cell apoptosis, wherein the decreased cardiac function, decreased heart weight, myocardial cell atrophy, myocardial tissue fibrosis, myocardial tissue oxidative stress, and myocardial cell apoptosis are induced after chemotherapy in tumor patients, and the chemotherapy drug is an anthracycline drug.

4. The use according to claim 3, characterized in that The anthracycline drug is doxorubicin.